Hinge Bio partners with Kyorin to Develop HB2198 in Japan

Hinge Bio, Inc., a private biotech firm that focuses on multispecific antibody medicines, announced a partnership with Kyorin Pharmaceutical Co., Ltd. They also signed a licensing deal. Kyorin is developing and selling HB2198 in Japan. It targets multiple autoimmune conditions, starting with Systemic Lupus Erythematosus (SLE).

こちらもお読みください： Celaid Therapeutics and AGC sign iPSC-HSPC research deal

Hinge Bio will get a US$ 10 million upfront payment. They can also earn up to US$ 95 million in milestone payments for the SLE indication. Plus, there are more milestone payments for future indications. Hinge Bio will lead the global development of HB2198. Kyorin Pharmaceutical will manage funding and development in Japan. They will also handle regulatory, marketing, and commercialization efforts. They will also help with global development. A Joint Steering Committee (JSC) has been formed. It will guide and may expand the program to cover various B cell-mediated autoimmune disorders.